Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Nov 3;13:1073726. doi: 10.3389/fphar.2022.1073726

Corrigendum: Activation of A2A receptor by PDRN reduces neuronal damage and stimulates WNT/β-catenin driven neurogenesis in spinal cord injury

Natasha Irrera 1, Vincenzo Arcoraci 1, Federica Mannino 1, Giovanna Vermiglio 2, Giovanni Pallio 1, Letteria Minutoli 1, Gianluca Bagnato 3, Giuseppe Pio Anastasi 2, Emanuela Mazzon 4, Placido Bramanti 4, Francesco Squadrito 1,*, Domenica Altavilla 2, Alessandra Bitto 1
PMCID: PMC9671133  PMID: 36408237

In the published article, the Conflict of interest statement was incorrect. The correct Conflict of interest statement appears below:

Conflict of interest

“The author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease. Author LM, FS and AB are co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest”.

The authors apologize for this error and state that this does not change the scientific conclusion of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES